Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial

Axel Grothey

doi:10.1007/s11888-009-0010-0

Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial

Axel Grothey

Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	65-66
Number of pages	2
Journal	Current Colorectal Cancer Reports
Volume	5
Issue number	2
DOIs	https://doi.org/10.1007/s11888-009-0010-0
State	Published - Apr 2009

ASJC Scopus subject areas

Hepatology
Oncology
Gastroenterology

Access to Document

10.1007/s11888-009-0010-0

Cite this

@article{0261ff4d87f640d989bfd51bc7814b26,

title = "Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial",

author = "Axel Grothey",

year = "2009",

month = apr,

doi = "10.1007/s11888-009-0010-0",

language = "English (US)",

volume = "5",

pages = "65--66",

journal = "Current Colorectal Cancer Reports",

issn = "1556-3790",

publisher = "Current Medicine Group",

number = "2",

}

TY - JOUR

T1 - Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy

T2 - Results from the CAIRO2 trial

AU - Grothey, Axel

PY - 2009/4

Y1 - 2009/4

UR - http://www.scopus.com/inward/record.url?scp=77957074409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957074409&partnerID=8YFLogxK

U2 - 10.1007/s11888-009-0010-0

DO - 10.1007/s11888-009-0010-0

M3 - Comment/debate

AN - SCOPUS:77957074409

SN - 1556-3790

VL - 5

SP - 65

EP - 66

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

IS - 2

ER -

Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this